Immunovant, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMVT research report →
Companyimmunovant.com
Immunovant, Inc. , a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia.
- CEO
- Eric Venker
- IPO
- 2019
- Employees
- 362
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $7.22B
- P/E
- -13.88
- P/S
- 0.00
- P/B
- 6.53
- EV/EBITDA
- -12.94
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -65.80%
- ROIC
- -49.40%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-505,606,000 · -22.17%
- EPS
- $-2.77 · -1.47%
- Op Income
- $0
- FCF YoY
- -8.15%
Performance & Tape
- 52W High
- $36.27
- 52W Low
- $13.79
- 50D MA
- $26.38
- 200D MA
- $22.86
- Beta
- 0.70
- Avg Volume
- 1.40M
Get TickerSpark's AI analysis on IMVT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | Susman Robert Graham | sell | 2,502 |
| Apr 23, 26 | Girao Tiago | sell | 25,760 |
| Apr 23, 26 | Stout Jay S | sell | 2,754 |
| Apr 8, 26 | Van Tuyl Christopher | sell | 5,165 |
| Apr 8, 26 | Gloria Melanie | sell | 8,722 |
| Apr 8, 26 | Stout Jay S | sell | 8,614 |
| Apr 8, 26 | Stout Jay S | sell | 1,518 |
| Apr 7, 26 | Torti Frank | other | 174,189 |
| Apr 7, 26 | Torti Frank | other | 88,325 |
| Apr 7, 26 | Fromkin Andrew J. | other | 13,880 |
Our IMVT Coverage
We haven't published any research on IMVT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IMVT Report →